Literature DB >> 24903995

A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus.

Barbara Ruszkowska-Ciastek1, Alina Sokup, Maciej W Socha, Zofia Ruprecht, Lidia Hałas, Barbara Góralczyk, Krzysztof Góralczyk, Grażyna Gadomska, Danuta Rość.   

Abstract

OBJECTIVE: Decompensated chronic hyperglycemia often leads to late microvascular complications such as retinopathy, diabetic foot syndrome, and diabetic kidney disease. The aim of this study was to determine the concentration of vascular endothelial growth factor A (VEGF-A) and its receptors in patients with well-controlled diabetes.
METHODS: The study was conducted on 31 patients with well-controlled type 2 diabetes without micro- or macroangiopathy. Thirty healthy volunteers were enrolled in a control group. Serum concentrations of VEGF-A, VEGF receptors 1 and 2 (VEGFR1 and VEGFR2), fasting glucose, and lipid profiles were measured, and the plasma concentration of glycated hemoglobin (HbA1c) was determined.
RESULTS: No significant differences were observed between the concentration of VEGF-A, VEGFR1 or VEGFR2 in the subject group and that in the control group. Positive correlations were noted between the levels of VEGF-A, VEGFR2, and triglyceride, and there was a negative correlation between the levels of VEGFR2 and high-density lipoprotein (HDL)-cholesterol in the study group.
CONCLUSIONS: The concentrations of VEGF-A and its receptors 1 and 2 in patients with well-controlled diabetes are comparable to those of healthy individuals, which may indicate that appropriate control of glucose levels delays the occurrence of vascular complications. A negative correlation between VEGFR2 and HDL-cholesterol levels, and positive correlations between VEGF-A, VEGFR2, and triglyceride levels, suggest that lipid abnormalities occurring in diabetes may be involved in the modulation of angiogenesis.

Entities:  

Keywords:  Angiogenesis; Glycated hemoglobin (HbA1c); Lipid abnormalities; Type 2 Diabetes

Mesh:

Substances:

Year:  2014        PMID: 24903995      PMCID: PMC4116851          DOI: 10.1631/jzus.B1400024

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  19 in total

1.  The role of vascular endothelial growth factor in the progression of diabetic vascular complications.

Authors:  R A Mahdy; W M Nada; K M Hadhoud; S A El-Tarhony
Journal:  Eye (Lond)       Date:  2010-05-28       Impact factor: 3.775

2.  Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy.

Authors:  Nan Hee Kim; Jeong Heon Oh; Ji A Seo; Kye Won Lee; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi; Young Sun Kang; Sang Youb Han; Kum Hyun Han; Yi Hwa Ji; Dae Ryong Cha
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

Review 3.  [Angiogenesis and neoangiogenesis--the role in lung cancer and other tumors].

Authors:  Ewa Swidzińska; Wojciech Naumnik; Elzbieta Chyczewska
Journal:  Pneumonol Alergol Pol       Date:  2006

Review 4.  Structure and function of VEGF receptors.

Authors:  Edward Stuttfeld; Kurt Ballmer-Hofer
Journal:  IUBMB Life       Date:  2009-09       Impact factor: 3.885

Review 5.  Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.

Authors:  N E Cameron; S E Eaton; M A Cotter; S Tesfaye
Journal:  Diabetologia       Date:  2001-11       Impact factor: 10.122

6.  Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria.

Authors:  F Santilli; A Spagnoli; A Mohn; S Tumini; A Verrotti; F Cipollone; A Mezzetti; F Chiarelli
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

7.  Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.

Authors:  Antonella N Witmer; Harriet G Blaauwgeers; Herbert A Weich; Kari Alitalo; Gijs F J M Vrensen; Reinier O Schlingemann
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

8.  Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus.

Authors:  Peter Kubisz; Peter Chudý; Ján Stasko; Peter Galajda; Pavol Hollý; Robert Vysehradský; Marián Mokán
Journal:  Acta Diabetol       Date:  2009-05-13       Impact factor: 4.280

Review 9.  Endothelial dysfunction in insulin resistance and type 2 diabetes.

Authors:  P-A Jansson
Journal:  J Intern Med       Date:  2007-08       Impact factor: 8.989

Review 10.  Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress?

Authors:  Basma Basha; Samson Mathews Samuel; Chris R Triggle; Hong Ding
Journal:  Exp Diabetes Res       Date:  2012-02-28
View more
  12 in total

1.  Effects of concomitant diabetes mellitus and hyperthyroidism on testicular and epididymal histoarchitecture and steroidogenesis in male animals.

Authors:  Nazar Ali Korejo; Quan-Wei Wei; Atta Hussain Shah; Fang-Xiong Shi
Journal:  J Zhejiang Univ Sci B       Date:  2016 Nov.       Impact factor: 3.066

2.  Low-grade risk of hypercoagulable state in patients suffering from diabetes mellitus type 2.

Authors:  Barbara Ruszkowska-Ciastek; Alina Sokup; Tomasz Wernik; Piotr Rhone; Krzysztof Góralczyk; Kornel Bielawski; Agata Fijałkowska; Aleksandra Nowakowska; Elżbieta Rhone; Danuta Rość
Journal:  J Zhejiang Univ Sci B       Date:  2015-09       Impact factor: 3.066

3.  Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.

Authors:  Radosław Wieczór; Grażyna Gadomska; Barbara Ruszkowska-Ciastek; Katarzyna Stankowska; Jacek Budzyński; Jacek Fabisiak; Karol Suppan; Grzegorz Pulkowski; Danuta Rość
Journal:  J Zhejiang Univ Sci B       Date:  2015-11       Impact factor: 3.066

4.  [Comparative study of differentiation potential of mesenchymal stem cells derived from orofacial system into vascular endothelial cells].

Authors:  J Xie; Y M Zhao; N Q Rao; X T Wang; T Jz Fang; X X Li; Y Zhai; J Z Li; L H Ge; Y Y Wang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-10-18

5.  [Clinical study of local injection of autologous platelet-rich plasma in treatment of diabetic foot ulcer].

Authors:  Xinyuan Qin; Jiangning Wang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-12-15

6.  Protective effects of scutellarin on type II diabetes mellitus-induced testicular damages related to reactive oxygen species/Bcl-2/Bax and reactive oxygen species/microcirculation/staving pathway in diabetic rat.

Authors:  Lingli Long; Jingnan Wang; Xiaofang Lu; Yuxia Xu; Shuhui Zheng; Canqiao Luo; Yubin Li
Journal:  J Diabetes Res       Date:  2015-03-12       Impact factor: 4.011

7.  Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway.

Authors:  Lingli Long; Han Qiu; Bing Cai; Ningning Chen; Xiaofang Lu; Shuhui Zheng; Xiaoxin Ye; Yubin Li
Journal:  Oncotarget       Date:  2018-01-04

8.  VEGFR2 alteration in Alzheimer's disease.

Authors:  Sun-Jung Cho; Moon Ho Park; Changsu Han; Keejung Yoon; Young Ho Koh
Journal:  Sci Rep       Date:  2017-12-18       Impact factor: 4.379

9.  Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis.

Authors:  Mohammad Ishraq Zafar; Kerry Mills; Xiaofeng Ye; Brette Blakely; Jie Min; Wen Kong; Nan Zhang; Luoning Gou; Anita Regmi; Sheng Qing Hu; Juan Zheng; Lu-Lu Chen
Journal:  Diabetol Metab Syndr       Date:  2018-08-03       Impact factor: 3.320

10.  Extracellular vesicles in diabetes mellitus induce alterations in endothelial cell morphology and migration.

Authors:  Sharon F Wu; Nicole Noren Hooten; David W Freeman; Nicolle A Mode; Alan B Zonderman; Michele K Evans
Journal:  J Transl Med       Date:  2020-06-09       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.